/LRMR
LRMR Stock - Larimar Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$3.65+6.41%
+$0.22 (+6.41%) • Dec 19
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.62
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.78
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+91.8%upside
Target: $7.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LRMR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.61 – $3.69
TARGET (TP)$7.00
STOP LOSS$3.36
RISK/REWARD1:11.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.05
52W High$5.37
52W Low$1.61
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-155,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-90,890,000 | $-41,758,000 | $-36,526,000 | $-50,465,000 | $-42,804,000 |
| Net Income | $-80,604,000 | $-36,949,000 | $-35,355,000 | $-50,636,000 | $-42,327,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.32 | $-0.84 | $-1.33 | $-2.93 | $-3.56 |
Company Overview
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish0 Neutral/Bearish
Price Targets
$17
Average Target
↑ 374.3% Upside
Now
$5
Low
$17
Average
$26
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 29th 2025 | Truist | Initiation | Buy | $18 |
| October 16th 2024 | Oppenheimer | Initiation | Outperform | $26 |
| October 3rd 2024 | Wedbush | Initiation | Outperform | $22 |
| October 2nd 2024 | H.C. Wainwright | Initiation | Buy | $15 |
| September 4th 2024 | Robert W. Baird | Initiation | Outperform | $16 |
| April 3rd 2024 | Leerink Partners | Initiation | Outperform | $25 |
| November 17th 2023 | Citigroup | Upgrade | Buy | $4.5 |
| October 19th 2022 | Guggenheim | Initiation | Buy | $12 |
Earnings History & Surprises
LRMRBeat Rate
58%
Last 19 quarters
Avg Surprise
+4.4%
EPS vs Estimate
Beats / Misses
11/8
Last 12 quarters
Latest EPS
$-0.61
Q4 2025
EPS Surprise History
Q1 24
-20.0%
$-0.30vs$-0.25
Q2 24
-12.5%
$-0.27vs$-0.24
Q3 24
-6.3%
$-0.34vs$-0.32
Q4 24
+35.1%
$-0.24vs$-0.37
Q1 25
-55.2%
$-0.45vs$-0.29
Q2 25
-9.5%
$-0.46vs$-0.42
Q3 25
+12.8%
$-0.41vs$-0.47
Q4 25
-56.4%
$-0.61vs$-0.39
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | $-0.43 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.39 | $-0.61 | -56.4% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.47 | $-0.41 | +12.8% | ✓ BEAT |
Q2 2025 | Apr 30, 2025 | $-0.42 | $-0.46 | -9.5% | ✗ MISS |
Q1 2025 | Mar 24, 2025 | $-0.29 | $-0.45 | -55.2% | ✗ MISS |
Q4 2024 | Oct 30, 2024 | $-0.37 | $-0.24 | +35.1% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.32 | $-0.34 | -6.3% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.24 | $-0.27 | -12.5% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.25 | $-0.30 | -20.0% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.23 | $-0.21 | +8.7% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.21 | $-0.19 | +9.5% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.25 | $-0.15 | +40.0% | ✓ BEAT |
Q1 2023 | Mar 14, 2023 | $-0.78 | $-0.21 | +73.1% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.50 | $-0.37 | +26.0% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.62 | $-0.47 | +24.2% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.62 | $-0.49 | +21.0% | ✓ BEAT |
Q1 2022 | Mar 25, 2022 | $-0.72 | $-0.50 | +30.6% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $-0.62 | $-0.92 | -48.4% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.73 | $-0.79 | -8.2% | ✗ MISS |
Q2 2021 | May 10, 2021 | $-0.93 | $-0.76 | +18.3% | ✓ BEAT |
Latest News
Larimar Therapeutics Q3 EPS $(0.61) Misses $(0.40) Estimate
📉 NegativeBenzinga•Nov 5, 2025, 12:09 PM
Oppenheimer Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $21
➖ NeutralBenzinga•Oct 2, 2025, 01:27 PM
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11
➖ NeutralBenzinga•Sep 30, 2025, 12:47 PM
Baird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $7
📈 PositiveBenzinga•Sep 30, 2025, 11:42 AM
Market-Moving News for September 29th
➖ NeutralBenzinga•Sep 29, 2025, 11:20 AM•Also: ,
Larimar shares are trading lower after the company reported seven patients experienced anaphylaxis and were withdrawn from its long-term study evaluating daily subcutaneous injections of nomlabofusp.
📉 NegativeBenzinga•Sep 29, 2025, 11:06 AM
Larimar Says Seven OL Study Participants Experienced Anaphylaxis And Were Withdrawn From The Study
📉 NegativeBenzinga•Sep 29, 2025, 11:05 AM
Larimar Therapeutics Announces Data From Ongoing Long-term Open Label Study; Co. Says It Consulted Its Experts And Decided To Modify Its Starting Dose Regimen
➖ NeutralBenzinga•Sep 29, 2025, 11:04 AM
Reported Sunday, Larimar To Provide Nomlabofusp Program Update For Friedreich's Ataxia During Conference Call And Webcast On September 29
➖ NeutralBenzinga•Sep 29, 2025, 06:33 AM
JMP Securities Reiterates Market Outperform on Larimar Therapeutics, Maintains $18 Price Target
📈 PositiveBenzinga•Aug 19, 2025, 12:52 PM
Larimar Therapeutics drops 20% as it announces public offering
📉 NegativeSeeking Alpha•Jul 29, 2025, 08:08 PM
Frequently Asked Questions about LRMR
What is LRMR's current stock price?
Larimar Therapeutics, Inc. (LRMR) is currently trading at $3.65 per share. The stock has moved +6.41% today.
What is the analyst price target for LRMR?
The average analyst price target for LRMR is $7.00, based on 1 analyst.
What sector is Larimar Therapeutics, Inc. in?
Larimar Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LRMR's market cap?
Larimar Therapeutics, Inc. has a market capitalization of $0.31 billion, making it a small-cap company.
Does LRMR pay dividends?
No, Larimar Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.03
Mkt Cap: $0.3B
ALT
Altimmune, Inc.
$3.90
Mkt Cap: $0.3B
AMRN
Amarin Corporation plc
$13.80
Mkt Cap: $0.3B
ANNX
Annexon, Inc.
$5.17
Mkt Cap: $0.6B
ANRO
Alto Neuroscience, Inc.
$19.98
Mkt Cap: $0.6B
DBVT
DBV Technologies S.A.
$22.76
Mkt Cap: $0.5B
ENGN
enGene Holdings Inc.
$8.69
Mkt Cap: $0.4B
KRRO
Korro Bio, Inc.
$7.88
Mkt Cap: $0.1B
KYTX
Kyverna Therapeutics, Inc.
$7.19
Mkt Cap: $0.3B
LXEO
Lexeo Therapeutics, Inc. Common Stock
$10.35
Mkt Cap: $0.8B
Explore stocks similar to LRMR for comparison